Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure
N/A
Active, not recruiting
NCT04334668
| Condition | Volume Overload |
|---|
| Phase | N/A |
|---|
| Sponsor | The Cleveland Clinic |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 67 participants |
|---|
| Interventions | Oral Sodium Chloride |
|---|
| Start date | May 20, 2020 |
|---|
| Completion date | Jun 1, 2022 |
|---|
| Results posted | Mar 12, 2024 |
|---|
Summary
The investigators are proposing a prospective, randomized, double blinded, placebo-controlled single center study evaluating the role of co-administration of oral sodium chloride (NaCl) with intravenous diuretics in patients hospitalized with acute decompensated heart failure. The investigators are approaching this study with the hypothesis that the use of oral sodium chloride leads to improved effective diuresis (as measured by weight loss) and renal function as compared to placebo in patients hospitalized with acute decompensated heart failure undergoing aggressive intravenous diuretic therapy.
Change in Weight
Baseline to 96 hours · Kilograms
| Oral Sodium Chloride | -3.9 ± 4.3 Kilograms |
|---|
| Placebo | -4.6 ± 4.2 Kilograms |
|---|
Change in Creatinine
Baseline to 96 hours · mEq/L
| Oral Sodium Chloride | 0.038 ± 0.39 mEq/L |
|---|
| Placebo | 0.15 ± 0.44 mEq/L |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.